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P
ioneering work by Anfinsen established that the fold-
ing of a polypeptide is dictated by its primary
sequence.1 The study of folding remains an active
area of research and a question of emerging impor-
tance is how the special challenges imposed by the
cytoplasm (e.g., high protein load, molecular crowding, and
dynamic oligomerization) impact this process. Given the
opportunities for off-pathway interactions and the threat of
catastrophic aggregation, the cellular environment certainly
offers unique challenges. To overcome these difficulties, cells
express molecular chaperones, a family of abundant, evolu-
tionarily conserved proteins that directly bind to protein
substrates. These interactions have many consequences,
including more efficient folding of nascent polypeptides and
stabilization of the folding trajectory. However, chaperones
also control many other aspects of a protein’s life and death,
including effects on aggregation, assembly into multiprotein
complexes, subcellular transport, and degradation.2 In these
various tasks, some chaperones appear to interact with a
large percentage of the proteome,3 whereas others bind to a
more restricted selection of substrates, for example, only spe-
cific components of chromatin4 or the proteasome.5,6
Of the molecular chaperones, the heat shock proteins are
a powerful defense against environmental insults, such as
thermal or oxidative stress.2 The heat shock proteins are typi-
cally categorized by their average molecular weight, with the
major classes being Hsp40, Hsp60, Hsp70, Hsp90, Hsp104,
Hsp110, and the small heat shock proteins. In the cell, mem-
bers of these categories appear to play distinct roles, and con-
sequently, they exhibit little structural or sequence homol-
ogy.7 However, in response to stress, they share the feature of
markedly increased expression. Moreover, many of the heat
shock proteins are thought to work together toward the goal
of shaping the proteome. For example, Hsp70 and Hsp90
cooperate in the folding and trafficking of nuclear hormone
receptors,8 and the function of many Hsp40s is thought to
occur via their actions on Hsp70. In addition, it is becoming
increasingly evident that the heat shock proteins are inte-
grated with the ubiquitin-proteasome system, endoplasmic
reticulum-associated degradation, the unfolded protein
response, apoptosis signaling, the chaperone-mediated
autophagy pathway and other cellular quality control sys-
tems. Collectively, these systems describe a proteostasis
network,9 which regulates cellular fate through managing
proteome integrity. Understanding the logic of this system
will likely require more detailed knowledge of how the com-
ponents are interconnected in both cells and organisms.
Toward this goal, attempts to mathematically model the
chaperone network are an important addition10,11 and
unbiased interaction maps should also be informative.12
Beyond their roles in fundamental protein homeostasis,
molecular chaperones are emerging drug targets. Many dis-
eases are characterized by disregulation of proteostasis,
including the classic examples of protein misfolding disor-
ders, such as cystic fibrosis and Alzheimer’s disease.13 Despite
a clear role for aberrant protein processing in these disorders,
the path to therapeutic rescue of folding balance remains
uncertain. One expected benefit of a deeper understanding of
chaperone biology is the ability to predict new drug targets
and strategies. In support of this idea, inhibitors of the
Hsp90 chaperone are currently being explored in multiple
oncology clinical trials. Inhibition of Hsp90 has been shown
to reduce the stability of prosurvival substrates, resulting in
apoptosis of susceptible cells.14 It seems likely that other
nodes within the cellular quality control network will also
prove to be amenable to pharmacological targeting. However,
chaperones often act on a large subset of the proteome,
which means that achieving the desired therapeutic out-
comes without concurrent toxicity will involve a delicate
balance. In contrast, chemicals that add folding energy to
specific misfolding-prone targets have also been explored in
protein misfolding diseases.15 Although these strategies
involve more selectivity, chemical optimization is required
for each target that generates a distinct set of design chal-
lenges. It seems that a combination of strategies will likely be
the best long-term scenario.
In this Special Series, experts in the field provide compre-
hensive updates on the most recent developments in the
study of molecular chaperones, protein folding, and disease.
In navigating this Special Series, one important question to
consider is: what are some major, current goals of the field?
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There are certainly no ‘‘correct’’ answers but linking biophys-
ical and structural studies to the cellular environment
remains a challenge. Additionally, understanding the logic of
the proteostasis network and the connectivity of the quality
control pathways are areas of interest. How do the chaper-
ones interact with each other and with their substrates? How
can these networks be tuned to rescue diseased systems?
Paralleling the remarkable diversity of publications in this
area, manuscripts within this Special Series discuss the major
issues from different points of view. For example, Johnson
and Zuehlke provide an excellent overview of Hsp90 biology,
and how this molecular chaperone operates in the specific
context of its associated cochaperones. They summarize
recent evidence that combinatorial assembly of multichaper-
one complexes might provide more robust folding outcomes.
Witt contributes an in-depth analysis of the Hsp70 chaper-
one, and how the structural and biochemical properties of
this machine might be exploited in Parkinson’s disease. He
specifically addresses the possibilities for pharmacological
intervention, and how the rationale for this approach
emerged from the basic biology. Following a conceptually
similar design, but on a distinct chaperone with unique biol-
ogy, Lashuel and Grimminger-Marquardt provide a compre-
hensive look at Hsp104. These authors nicely demonstrate
how biophysical and structural studies of this chaperone
have contributed to our understanding of protein processing.
Cyr and Douglas add a fascinating look into how networks
of chaperones impinge on protein aggregation and they high-
light how both pro- and anti-aggregation outcomes can be
beneficial. Finally, one of the emerging areas in chaperone
biology is to exploit new findings for biotechnological pur-
poses. Accordingly, Fisher and his colleagues suggest interest-
ing, new applications of the chaperonin, GroEL. They show
how GroEL can be used to both identify chemical probes
and understand protein folding/misfolding propensities.
Together, these articles are intended to provide an overview
of the major chaperone systems, their connections, and their
potential roles in disease.
JASON E. GESTWICKI
Department of Pathology
and the Life Sciences Institute
University of Michigan
210 Washtenaw Ave
Ann Arbor, MI 48109-2216
REFERENCES
1. Anfinsen, C. B. Science 1973, 181, 223–230.
2. Bukau, B.; Weissman, J.; Horwich, A. Cell 2006, 125, 443–451.
3. Rudiger, S.; Germeroth, L.; Schneider-Mergener, J.; Bukau,
B. EMBO J 1997, 16, 1501–1507.
4. Huang, S.; Zhou, H.; Katzmann, D.; Hochstrasser, M.; Ata-
nasova, E.; Zhang, Z. Proc Natl Acad Sci USA 2005, 102,
13410–13415.
5. Kaneko, T.; Hamazaki, J.; Iemura, S.-I.; Sasaki, K.; Fur-
uyama, K.; Natsume, T.; Tanaka, K.; Murata, S. Cell 2009,
137, 914–925.
6. Funakoshi, M.; Tomko, R. J.; Kobayashi, H.; Hochstrasser,
M. Cell 2009, 137, 887–899.
7. Vos, M. J.; Hageman, J.; Carra, S.; Kampinga, H. H. Bio-
chemistry 2008, 47, 7001–7011.
8. Pratt, W. B.; Morishima, Y.; Murphy, M.; Harrell, M.
Handb Exp Pharmacol 2006, 172, 111–138.
9. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Science
2008, 319, 916–919.
10. Hu, B.; Mayer, M. P.; Tomita, M. Biophys J 2006, 91, 496–507.
11. Wiseman, R. L.; Powers, E. T.; Buxbaum, J. N.; Kelly, J. W.;
Balch, W. E. Cell 2007, 131, 809–821.
12. Gong, Y.; Kakihara, Y.; Krogan, N.; Greenblatt, J. F.; Emili,
A.; Zhang, Z.; Houry, W. A. Mol Syst Biol 2009, 5, 1–14.
13. Dobson, C. M. Nature 2003, 426, 884–890.
14. Neckers, L. Handb Exp Pharmacol 2006, 259–277.
15. Bernier, V.; Lagace, M.; Bichet, D. G.; Bouvier, M. Trends
Endocrinol Metab 2004, 15, 222–228.
210 Editorial
Biopolymers
